Zevra Therapeutics Posts 78% Revenue Surge, Sells SDX Portfolio for $50M
Event summary
- Q1 2026 revenue hit $36.2M, up 78% YoY, driven by MIPLYFFA sales and SDX portfolio divestment.
- Completed $50M sale of SDX portfolio to Commave Therapeutics, repaying $63.1M term loan.
- MIPLYFFA prescription forms reached 170 in the U.S., with stable EU market access review.
- Enrolled 10 patients in Phase 3 DiSCOVER trial for Vascular Ehlers-Danlos Syndrome.
- Cash position strengthened to $236.8M, with adjusted net income of $11.5M.
The big picture
Zevra's Q1 2026 results highlight a strategic pivot toward core rare disease therapies, bolstered by a $50M divestment that eliminated debt and fortified its balance sheet. The company's focus on MIPLYFFA's expansion and celiprolol's Phase 3 trial reflects broader industry trends of targeted rare disease treatments and regulatory-driven development pathways. With $236.8M in cash, Zevra is well-positioned to navigate the capital-intensive biopharmaceutical landscape while advancing its pipeline.
What we're watching
- Regulatory Progress
- Whether the EMA's review of MIPLYFFA's Marketing Authorisation Application will advance smoothly, given the Orphan Medicinal Product designation.
- Pipeline Execution
- The pace at which the DiSCOVER trial for Vascular Ehlers-Danlos Syndrome enrolls patients and whether the FDA follow-up meeting accelerates development.
- Financial Flexibility
- How Zevra will deploy its strengthened cash position to fund pipeline advancements and potential acquisitions post-SDX divestment.
Related topics